Where are Australian consumers spending their money in this environment?

Macquarie research reveals new spending trends and the best ASX 200 retail stocks to buy now.

A senior pharmacist talks to a customer at the counter in a shop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Australian consumers are increasingly cautious in their spending, with a larger percentage of their wallets going toward essential items.

Macquarie's 1Q CY25 retail sales performance report reveals Australian consumers are spending more at large-format discount retailers.

These retailers include Kmart, owned by Wesfarmers Ltd (ASX: WES), BIG W, owned by Woolworths Group Ltd (ASX: WOW), and Chemist Warehouse, owned by Sigma Healthcare Ltd (ASX: SIG).

Australian consumers are also spending more with online international retailers selling low-cost non-discretionary products that make them feel good.

Top 5 brands for spending growth among Australian consumers

These trends are reflected in the top five brands for spending growth in 1Q CY25 vs 1Q CY24.

According to Macquarie, they were Temu, up 25.3%, Chemist Warehouse, up 17.5%, Amazon, up 15.4%, Drakes, up 14.2%, and Shein, up 13.5%.

Australian consumers are also shopping around between the major supermarkets, hunting for the best deals.

Aldi and Costco were the fastest-growing retailers in the grocery sector in 1Q CY25, with spending up 7% and 6%, respectively.

Macquarie says discounts are now "considered a way of life and not a budget tool" to help retailers retain customers.

The broker says:

Aldi exploits its "less is more" private label offer while creating interest with "Aldi Finds" through its treasure hunt.

Costco delivers lower prices with large expandable packs.

In terms of product categories, Australian consumers spent more on clothing and footwear, up 6.6%, fitness, up 4.7%, and home entertainment, up 4.2%, in 1Q CY25.

By contrast, consumers reduced their spending on automotive, down 7.1%, jewellery, down 4.4%, and dining out, down 4.2%.

Which ASX 200 retail shares are a buy?

Macquarie has an outperform rating on Coles Group Ltd (ASX: COL) shares with a 12-month target share price of $22. At the time of writing, the Coles share price is $21.42, up 0.16%.

The broker also has an outperform rating on Woolworths shares with a price target of $30.80. Currently, the Woolworths share price is $31.73, down 0.047%.

In the discretionary retail space, Macquarie has an outperform rating on JB Hi-Fi Ltd (ASX: JBH) with a share price target of $111. The JB Hi-Fi share price is currently $102.55, up 0.85%.

Macquarie is also backing Harvey Norman Holdings Ltd (ASX: HVN) shares with an outperform rating and a $5.50 price target. The ASX 200 retail stock is currently trading at $5.23, up 1.16%.

The broker also likes Treasury Wine Estates Ltd (ASX: TWE). It has an outperform rating on the ASX 200 wine share with a $11.70 price target. The Treasury Wine share price is currently $8.90, up 0.68%.

Macquarie says Chemist Warehouse is increasingly popular with Australian consumers and "remains one of the fastest growing brands in the country". However, the broker has an underperform rating on Sigma shares because it views the current valuation as full.

John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Amazon, Costco Wholesale, Macquarie Group, and Wesfarmers. The Motley Fool Australia has positions in and has recommended Coles Group, Harvey Norman, and Macquarie Group. The Motley Fool Australia has recommended Amazon, Jb Hi-Fi, Treasury Wine Estates, and Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
Growth Shares

These 4 ASX 200 stocks could jump another 70% to 80% in 2026

These stocks are expected to rocket higher.

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Share Gainers

3 ASX 200 stocks jumping higher in this week's falling market

Investors shrugged off the broader market retrace and piled into these three ASX 200 stocks this week.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why EOS, Lotus Resources, REA, and Web Travel shares are dropping today

These shares are ending the week deep in the red. But why?

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Brambles, HMC Capital, ResMed, and Rio Tinto shares are rising today

These shares are avoiding the selloff and are pushing higher on Friday.

Read more »

A woman looks shocked as she drinks a coffee while reading the paper.
Share Fallers

Why is the Web Travel share price crashing 41% on Friday?

ASX investors are pummelling Web Travel shares today. But why?

Read more »

A man looking at his laptop and thinking.
Materials Shares

Rio Tinto shares charge higher after Glencore merger collapses

The parties couldn't come to an agreement.

Read more »

a group of doctors and medical staff in uniform high five in celebration in a hospital setting
Share Market News

Neuren Pharmaceuticals kicks off Phase 3 trial in rare syndrome

Neuren Pharmaceuticals shares are on watch after dosing began in its key Phase 3 trial for Phelan-McDermid syndrome.

Read more »